Abstract OBJECTIVE: To investigate the efficacy, hematopoietic reconstitution, complications and survival of refractory relapsed malignant lymphoma treated with allogeneic hematopoietic stem cell transplantation (allo- HSCT). METHODS: From November 1999 to June 2006, 14 cases of refractory advanced lymphoma were treated with clear-marrow allo-HSCT. 3 cases received allogeneic peripheral blood stem cell transplantation (allo-PBSCT) with allogeneic human leukocyte antigen (HLA) compatibility, and 11 cases received allogeneic bone marrow transplantation (allo-BMT) with kinship haplotype compatibility. Graft-versus-host disease (GVHD) prophylaxis was performed by combining immunosuppressive agents: cyclocilin A and short-course aminoglycoside for allogeneic transplantation, and anti-thymocyte globulin, CD25 monoclonal antibody and mycophenolate in addition to the above drugs for haploidentical transplantation. The mean time to transplantation for neutrophils >0.5×109/L and platelets >20×109/L was 17.5 days and 21.5 days, respectively, and the implantation evidence test confirmed complete donor hematopoiesis. The median survival time was 57.8(38-96) months. Conclusion: allo-HSCT is an effective treatment for refractory malignant lymphoma with bone marrow invasion and relapse after autologous hematopoietic stem cell transplantation.